Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Triple Negative Breast Neoplasms × AZD 6244 × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 1 4 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Sarcoma, Kaposi 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pain 1 Neurofibrosarcoma 1 Neurofibroma, Plexiform 1 Neoplasms 1 Lung Neoplasms 1 Liver Neoplasms 1 Carcinoma, Hepatocellular 1 Astrocytoma 1 Acquired Immunodeficiency Syndrome 1 AIDS-related Kaposi sarcoma 1

Interventions

pembrolizumab 30 Nivolumab 14 Paclitaxel 13 Carboplatin 13 Cyclophosphamide 9 sacituzumab govitecan 7 Cisplatin 7 Capecitabine 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 Magnetic Resonance Spectroscopy 5 Biopsy 5 camrelizumab 4 atezolizumab 4 Specimen Handling 4 Ipilimumab 4 Interleukin-2 4 Injections 4 Immune Checkpoint Inhibitors 4 Gemcitabine 4 Docetaxel 4 toripalimab 3 talazoparib 3 fludarabine 3 avelumab 3 Immunoglobulin G 3 Everolimus 3 Clinical Trials, Phase II as Topic 3 spartalizumab 2 seviteronel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02583542 2020-02-25

TORCMEK

Queen Mary University of London

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡